<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Focal segmental glomerulosclerosis: Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Focal segmental glomerulosclerosis: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Focal segmental glomerulosclerosis: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Cattran, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">An S De Vriese, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Focal segmental glomerulosclerosis (FSGS) is a morphologic pattern of glomerular injury primarily directed at the glomerular visceral epithelial cell (the podocyte) and defined by the presence of sclerosis in parts (segmental) of some (focal) glomeruli by light microscopy of a kidney biopsy specimen. The lesion of FSGS can be classified into primary, secondary, genetic, and undetermined forms using a clinicopathologic approach. This classification step is crucial for determining appropriate therapy; identification of an FSGS lesion solely by light microscopy is never sufficient for management decisions. The lesion of FSGS is distinct from focal and global glomerulosclerosis, which has a different prognosis and treatment.</p><p>This topic will review the treatment and prognosis of the FSGS lesion in adults in all of its forms but will focus on patients with presumed primary FSGS. Other aspects of the FSGS lesion, including the treatment of children with FSGS lesions, the treatment of collapsing glomerulopathy, and the treatment of recurrent FSGS in the transplanted kidney, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney"</a>.)</p><p></p><p class="headingAnchor" id="H3189621559"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H2655864584"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>A primary goal of therapy in FSGS is remission of proteinuria, preferably a complete remission, with the long-term goal of preventing progression to end-stage kidney disease (ESKD). For patients with primary FSGS, remission of proteinuria is primarily achieved with the use of a variety of agents having both immunosuppressive properties as well as direct actions on glomerular podocytes (most commonly glucocorticoids or calcineurin inhibitors [CNIs]), as well as with supportive measures (such as renin-angiotensin inhibition). For patients with secondary FSGS, cessation of the offending drug or effective treatment of the underlying condition, combined with supportive measures, is the therapy of choice. Adults with proven genetic forms of FSGS usually do not respond to immunosuppressive therapy and should also be primarily treated with supportive measures. (See <a class="local">'Treatment of primary FSGS'</a> below and <a class="local">'Treatment of secondary FSGS or FSGS of undetermined cause'</a> below and <a class="local">'Treatment of genetic FSGS'</a> below.)</p><p class="headingAnchor" id="H2282065482"><span class="h2">Definitions of response</span><span class="headingEndMark"> — </span>The following are commonly used definitions of treatment response for adults with nephrotic syndrome due to primary FSGS [<a href="#rid1">1</a>]. These definitions are not necessarily evidence based and may need to be modified on a case-by-case basis by other factors, such as duration of therapy before switching or adding treatment. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete remission</strong> – A complete remission is reduction of proteinuria to &lt;300 mg/day (or &lt;300 mg/g of creatinine), stable serum creatinine, and serum albumin &gt;3.5 g/dL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial remission</strong> – A partial remission is a reduction in proteinuria to between 300 mg and 3.5 g/day and a decrease of &gt;50 percent from baseline, with or without a return of serum albumin levels to normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> – A relapse is a return of proteinuria to &gt;3.5 g/day in patients who had previously undergone a complete remission or an increase in proteinuria of &gt;50 percent in patients who had previously undergone a partial remission. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-resistant primary FSGS</strong> – Glucocorticoid resistance refers to the persistence of proteinuria &gt;3.5 g/day with ≤50 percent reduction from baseline after 16 weeks of high-dose oral glucocorticoid therapy (ie, oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day or 2 mg/kg every other day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-dependent primary FSGS</strong> – Glucocorticoid dependence refers to relapse occurring during, or within two weeks of completing, glucocorticoid therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcineurin inhibitor-resistant primary FSGS</strong> – CNI resistance refers to the persistence of proteinuria &gt;3.5 g/day with ≤50 percent reduction from baseline despite <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> treatment at trough levels of 100 to 175 ng/mL or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> treatment at trough levels of 5 to 10 ng/mL for four to six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcineurin inhibitor-dependent primary FSGS </strong>– CNI dependence refers to relapse occurring during, or within two weeks of completing, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> therapy for &gt;12 months.</p><p></p><p class="headingAnchor" id="H3714670633"><span class="h1">TREATMENT MEASURES FOR ALL FORMS OF FSGS</span><span class="headingEndMark"> — </span>General treatment measures in all patients with FSGS include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, treatment of dyslipidemia, and in selected patients, anticoagulation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may also be of benefit, although data specifically in patients with FSGS are limited [<a href="#rid2">2</a>]. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition. This approach is consistent with the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases [<a href="#rid1">1</a>]. These issues are discussed in greater detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary sodium and protein restriction (see  <a class="medical medical_review" href="/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Salt intake'</a> and  <a class="medical medical_review" href="/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Protein intake'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antihypertensive therapy (see  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renin-angiotensin system inhibition (see  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Renin-angiotensin system inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SGLT2 inhibitors (see  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipid lowering (see  <a class="medical medical_review" href="/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome", section on 'Management'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation (see  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Patients with other causes of nephrotic syndrome'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of edema (see  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Volume overload'</a>)</p><p></p><p class="headingAnchor" id="H4134349917"><span class="h1">TREATMENT OF PRIMARY FSGS</span></p><p class="headingAnchor" id="H3675741567"><span class="h2">Initial therapy</span></p><p class="headingAnchor" id="H4219147866"><span class="h3">General approach</span><span class="headingEndMark"> — </span>Our approach to initial therapy in patients with a clinicopathologic diagnosis of presumed primary (permeability factor-related) FSGS is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with presumed primary FSGS who present with nephrotic syndrome (ie, proteinuria &gt;3.5 g/day and serum albumin &lt;3.5 g/dL), we suggest initial treatment with glucocorticoids, rather than a calcineurin inhibitor (CNI). Such patients have a poor prognosis without this therapy. In patients who have a high risk for glucocorticoid-induced toxicity (eg, patients with obesity, diabetes, severe osteoporosis, or age &gt;70 years), a CNI (<a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>), with or without low-dose glucocorticoids, is an alternative option for initial therapy. However, we avoid using CNIs in patients with significantly reduced kidney function (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>) because of the potential nephrotoxicity of these drugs. All patients receiving glucocorticoids or a CNI should also be treated with general supportive measures. (See <a class="local">'Dosing and duration of initial therapy'</a> below and <a class="local">'Treatment measures for all forms of FSGS'</a> above.)</p><p></p><p class="bulletIndent1">Patients who are pregnant can generally be safely treated with glucocorticoids or a CNI. (See <a class="local">'Patients who are pregnant'</a> below.)</p><p></p><p class="bulletIndent1">Patients who cannot be treated with either glucocorticoids or a CNI are rare. In such cases, alternative options might include <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF)/enteric-coated mycophenolate sodium (EC-MPS), <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and adrenocorticotropic hormone (ACTH) gel, although there is no evidence to support the use of these agents as initial therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, we typically do <strong>not </strong>administer glucocorticoids or CNI therapy in patients who have the following clinical features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients without nephrotic syndrome – Patients without nephrotic syndrome (ie, patients with nephrotic-range proteinuria and normal serum albumin or those with subnephrotic proteinuria) who have normal kidney function typically have more indolent disease that either spontaneously remits or remains stable for years [<a href="#rid3">3-5</a>]. Patients without nephrotic syndrome who have decreased eGFR may have secondary FSGS, previously severe primary FSGS that progressed and went undiagnosed, or primary FSGS that was inadequately treated or resistant to standard therapies; such patients are less likely to respond to therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with histologic evidence of extensive glomerulosclerosis and interstitial fibrosis – These findings are manifestations of irreversible damage, particularly in patients with substantially reduced kidney function. Glucocorticoids or CNIs are unlikely to be beneficial in this setting.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients with secondary, genetic, or unknown forms of the FSGS lesion. (See <a class="local">'Treatment of secondary FSGS or FSGS of undetermined cause'</a> below and <a class="local">'Treatment of genetic FSGS'</a> below.)</p><p></p><p class="bulletIndent1">Patients with these clinical features are generally treated with supportive measures only. (See <a class="local">'Treatment measures for all forms of FSGS'</a> above.)</p><p></p><p>The recommendations for initial therapy with glucocorticoids are based primarily upon observational studies and the authors' clinical experience [<a href="#rid3">3,4,6-13</a>]. There are no randomized trials comparing <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or other agents with placebo for initial therapy of primary FSGS, using a modern definition of primary FSGS. Prednisone induces complete or partial remission in 40 to 80 percent of such patients with relatively preserved kidney function, and as discussed below, responders have better long-term outcomes (see <a class="local">'Prognosis'</a> below). The following studies illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In one report that evaluated the course of 55 adults (mean creatinine clearance of 90 mL/min) over a mean of 11 years, 18 were treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, 7 also received <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and the remainder were not treated [<a href="#rid9">9</a>]. Among the 18 treated patients, 8 (44 percent) achieved complete remission, compared with 4 of 37 (11 percent) untreated patients (2 of whom were never nephrotic). End-stage kidney disease (ESKD) occurred less frequently in treated nephrotic patients (29 versus 53 percent in untreated nephrotic patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 60 nephrotic and 21 non-nephrotic patients with FSGS, in which one-half of the nephrotic patients were treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, the 5- and 10-year kidney survival in the non-nephrotic patients was 92 percent, compared with 76 and 57 percent among the treated and non-treated nephrotic patients [<a href="#rid8">8</a>]. Among the treated nephrotic patients, one-half responded. The 5- and 10-year kidney survival among responders was 100 percent, compared with 65 and 40 percent among nonresponders, respectively.</p><p></p><p>Studies on <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> are restricted to glucocorticoid-resistant or glucocorticoid-dependent primary FSGS; there is only one uncontrolled study of initial therapy with <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. In this report, tacrolimus was administered to six patients with a mean protein excretion of 11 g/day who were being treated with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) but no immunosuppression [<a href="#rid14">14</a>]. All patients entered a partial remission with &gt;75 percent reduction in proteinuria (to a mean of 2.8 g/day) within a mean of six months. eGFR declined initially in two patients from &gt;90 to 50 mL/min/1.73 m<sup>2</sup> but subsequently stabilized. (See <a class="local">'Calcineurin inhibitors as preferred second-line therapy'</a> below.)</p><p class="headingAnchor" id="H4092636220"><span class="h3">Dosing and duration of initial therapy</span></p><p class="headingAnchor" id="H2371570901"><span class="h4">Glucocorticoids</span><span class="headingEndMark"> — </span>In patients initiating glucocorticoid therapy for primary FSGS, we administer treatment as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dose</strong> – We administer <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg per day (maximum dose 60 to 80 mg/day) with subsequent tapering of the dose. An alternative is to use 2 mg/kg every other day (maximum dose 120 mg every other day). The full dose should be given once daily around 9 or 10 AM, to minimize suppression of the hypophyseal-adrenal axis.</p><p></p><p class="bulletIndent1">Some prefer daily dosing for initial therapy in patients with no contraindications since failure to respond to alternate-day dosing would necessitate conversion to daily dosing and result in prolongation of the glucocorticoid course. However, alternate-day dosing may be a better option in patients at higher risk of complications due to glucocorticoids, including older adult patients and those who are obese.</p><p></p><p class="bulletIndent1">There is no high-quality evidence to guide the optimal dose and regimen (ie, daily or every other day) of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> therapy, and these dosing recommendations are extrapolated from doses used with success in observational studies and trials of other kidney diseases [<a href="#rid3">3,4,8-13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration and tapering</strong> – In general, the duration of therapy varies according to the degree and rapidity of response (eg, faster taper for patients who achieve a quick remission), whether complete or partial remission is achieved, and the degree of glucocorticoid toxicity (see <a class="local">'Definitions of response'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a complete remission is achieved within 8 to 12 weeks, we continue the initial dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> for one to two more weeks and then taper the dose over two to three months. One strategy is to switch to alternate-day prednisone (double the daily dose but to a maximum of 80 to 120 mg), and then decrease the dose by approximately one-third every two to three weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a partial remission is achieved by 8 to 12 weeks, we taper <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> slowly over three to nine months. We initially switch to alternate-day dosing and decrease the dose by one-third approximately every six weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have had a substantial reduction (&gt;50 percent from baseline) in proteinuria by 8 to 12 weeks but do not meet criteria for partial remission (ie, proteinuria remains &gt;3.5 g/day), the decision to continue high-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or modify therapy is based upon the severity of glucocorticoid toxicity, the risk of continued therapy, and whether protein excretion is continuing to fall. Prednisone can be continued, for example, in patients whose proteinuria continues to decline, provided they are not experiencing severe side effects from therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If, at any time after a complete or partial remission is attained, proteinuria increases while the <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is being tapered, we stop the taper and temporarily maintain the current prednisone dose while adding a CNI or, if the eGFR is &lt;30 mL/min/1.73 m<sup>2</sup>, MMF/EC-MPS. Although the use of MMF/EC-MPS is not supported by evidence, some authors and editors of this topic use it in this setting based on its potential role as a glucocorticoid-sparing agent, its safe use in patients with low eGFR, and its role as maintenance therapy in other glomerular diseases such as minimal change disease and lupus nephritis. (See <a class="local">'Glucocorticoid-dependent or glucocorticoid-resistant disease'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adult patients who have little or no reduction in proteinuria after 16 weeks of daily <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> are presumed to be glucocorticoid resistant. In such patients, we prefer to add a CNI (or MMF if the eGFR is low) and switch to alternate-day prednisone with a progressive taper in prednisone therapy, reducing the dose by approximately one-third every week. (See <a class="local">'Glucocorticoid-dependent or glucocorticoid-resistant disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Side effects associated with use of glucocorticoids are discussed separately. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="headingAnchor" id="H1893065838"><span class="h4">Calcineurin inhibitors as alternative initial therapy</span><span class="headingEndMark"> — </span>CNIs are an acceptable alternative option for initial therapy in patients who are at increased risk for glucocorticoid-associated toxicity, although supportive evidence is limited [<a href="#rid15">15</a>]. We avoid using CNIs in patients who have significant vascular or interstitial disease on kidney biopsy, or a chronic reduction in kidney function with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, because of the potential nephrotoxicity of these drugs.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dose</strong> – If a CNI is used, either <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> is a reasonable choice. Cyclosporine has been studied more extensively than tacrolimus in patients with FSGS. However, there are advantages to tacrolimus, which is used extensively in kidney transplantation and has been studied in other glomerular diseases such as minimal change disease (see  <a class="medical medical_review" href="/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults"</a>). As an example, tacrolimus is associated with a lower risk of cosmetic side effects (eg, hirsutism, gingival hyperplasia); thus, many clinicians prefer tacrolimus over cyclosporine as the CNI of choice, especially in females.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is used, initial dosing is 3 to 5 mg/kg per day in two divided doses, with dose adjustments as necessary to target a trough level between 100 and 175 ng/mL. Some authors use a starting dose of 200 mg twice daily in males and 100 to 150 mg twice daily in females and titrate up the dose as needed to achieve target levels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> is used, initial dosing is 0.05 to 0.1 mg/kg per day in two divided doses, with dose adjustments as necessary to target a trough level between 5 and 10 ng/mL. Some authors use a starting dose of 1 mg twice daily in smaller-sized females (weight &lt;60 kg) or 2 mg twice daily in males and larger-sized females and titrate up the dose as needed to achieve target levels.</p><p></p><p class="bulletIndent1">Dose adjustments are typically made in small increments with subsequent drug concentration monitoring. Certain foods (eg, grapefruit or grapefruit juice) and drugs (eg, those metabolized by, or that affect metabolism by, cytochrome P-450 3A4/5 enzymes) can interact with CNIs and affect drug concentrations. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Food and drug interactions'</a>.)</p><p></p><p class="bulletIndent1">Some experts use low-dose glucocorticoid therapy in combination with CNIs, but supportive evidence for such a combination is weak. If <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is used, we give 0.15 mg/kg per day (maximum 15 mg/day) or 0.4 mg/kg (approximately 30 mg) every other day. After six months, we taper prednisone to 5 mg/day (or 10 mg on alternate days) and maintain it along with the CNI for an additional 6 to 12 months after attaining a remission. In patients with significant glucocorticoid toxicity, we taper prednisone earlier with the goal of discontinuation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration</strong> – We continue <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> for at least six months following attainment of a complete remission and for at least 12 months following attainment of a partial remission but at the lowest dose required to maintain remission. The dose can then be slowly tapered over 6 to 12 months as tolerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Side effects associated with use of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p></p><p>Patients are unlikely to respond if there is little or no reduction in protein excretion after four to six months; the CNI should be discontinued in such patients with CNI resistance, and an alternative therapy should be attempted. (See <a class="local">'Glucocorticoid-dependent or glucocorticoid-resistant disease'</a> below.)</p><p class="headingAnchor" id="H1174154946"><span class="h3">Monitoring the response to therapy</span><span class="headingEndMark"> — </span>All patients who are receiving treatment for primary FSGS should be closely monitored for their clinical response to therapy. Definitions of clinical response are presented elsewhere in this topic. (See <a class="local">'Definitions of response'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients receiving glucocorticoid or CNI therapy</strong> – In all patients receiving glucocorticoid or CNI therapy, we obtain a serum creatinine concentration, electrolytes, and a urine protein-to-creatinine ratio (UPCR) every two to four weeks during the initial two to three months of therapy. Prior to tapering immunosuppression, some authors confirm the level of proteinuria with a 24-hour urine collection. Once drug therapy is stabilized and/or is being tapered, we monitor laboratory studies every one to two months.</p><p></p><p class="bulletIndent1">In patients who are being treated with a CNI, we measure the serum creatinine and electrolytes and a whole blood trough level of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> approximately one week (7 to 10 days) after initiating therapy to monitor for acute nephrotoxicity and hyperkalemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients receiving supportive measures only</strong> – In patients who are receiving supportive measures only, we obtain a serum creatinine, electrolytes, and a UPCR every three to four months until these parameters stabilize and then every three to six months thereafter. </p><p></p><p>We generally do not repeat a kidney biopsy in patients with primary FSGS unless there are signs of disease progression and it is uncertain if another factor may be responsible. A biopsy may also be indicated in a patient who develops an unexpected or severe relapse and there is concern for transformation to the collapsing form of FSGS, which may require more aggressive therapy. (See  <a class="medical medical_review" href="/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)"</a>.)</p><p class="headingAnchor" id="H2579393721"><span class="h2">Relapsing disease</span><span class="headingEndMark"> — </span>Relapse occurs in approximately 25 to 35 percent of patients after a complete remission and in more than 50 percent of patients with a partial remission [<a href="#rid3">3,9,12</a>]. The timing of first relapse may range from 4 to 23 months following a complete remission [<a href="#rid16">16</a>]. (See <a class="local">'Definitions of response'</a> above.)</p><p>Patients who achieve a remission and then develop a relapse at least several months after discontinuation of therapy are considered to have a late relapse. By contrast, patients who previously had a complete or partial response to glucocorticoids (or a calcineurin inhibitor [CNI]) but relapse during the taper or within two weeks after cessation of glucocorticoid (or CNI) therapy are considered glucocorticoid dependent (or CNI dependent). Treatment of such patients is described in the next section. (See <a class="local">'Glucocorticoid-dependent or glucocorticoid-resistant disease'</a> below.)</p><p>Treatment of late relapse in primary FSGS has not been evaluated in controlled trials; the suggestions below are based upon personal experience and limited observational data. The approach to this problem varies with the response to initial therapy and the time to relapse:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids as initial therapy</strong> – If the patient previously had a complete or partial remission with glucocorticoids, did not have significant side effects, has not developed a condition that increases the risk of glucocorticoid-induced toxicity, and has been in remission for a prolonged period (eg, at least four to six months) after discontinuation of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, then we repeat a course of prednisone. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1">However, if the patient had significant glucocorticoid-induced toxicity during initial therapy, has developed a condition that increases the risk of glucocorticoid-induced toxicity, or has had multiple relapses, then we usually treat with a CNI, with or without low-dose glucocorticoids, using a regimen similar to that described above. In such patients who have substantially reduced estimated glomerular filtration rate (eGFR; eg, &lt;30 mL/min per 1.73 m<sup>2</sup>), we prefer <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF)/enteric-coated mycophenolate sodium (EC-MPS) combined with low-dose glucocorticoids rather than a CNI, although evidence to support this approach is weak. <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is another possible alternative to a CNI, particularly for patients with frequent relapses, but data are mixed in terms of response. The MMF/EC-MPS and rituximab regimens are described below. (See <a class="local">'Calcineurin inhibitors as alternative initial therapy'</a> above and <a class="local">'Other therapies for patients resistant or intolerant to a calcineurin inhibitor'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNI as initial therapy</strong> – If the patient previously had a complete or partial remission with a CNI, did not have significant side effects, and has been in remission for a prolonged period (eg, at least four to six months) after discontinuation of the CNI, then we repeat a course of CNI therapy. However, if the patient cannot receive a CNI because of prior toxicity or reduced eGFR (&lt;30 mL/min per 1.73 m<sup>2</sup>), MMF/EC-MPS or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is a possible alternative. (See <a class="local">'Calcineurin inhibitors as alternative initial therapy'</a> above and <a class="local">'Other therapies for patients resistant or intolerant to a calcineurin inhibitor'</a> below.)</p><p></p><p class="headingAnchor" id="H3754138819"><span class="h2">Glucocorticoid-dependent or glucocorticoid-resistant disease</span><span class="headingEndMark"> — </span>Patients who will respond to glucocorticoid therapy generally start to show some reduction in proteinuria within the first 8 to 12 weeks of therapy. Patients who attain a remission but who relapse while still on therapy or within two weeks of discontinuing therapy are considered glucocorticoid dependent. Adult patients with little or no reduction in proteinuria at 16 weeks are considered glucocorticoid resistant.</p><p class="headingAnchor" id="H3303023964"><span class="h3">Calcineurin inhibitors as preferred second-line therapy</span><span class="headingEndMark"> — </span>For patients with glucocorticoid-dependent or glucocorticoid-resistant FSGS (see <a class="local">'Definitions of response'</a> above), we recommend treatment with a calcineurin inhibitor (CNI) rather than continued glucocorticoids or no therapy. For patients with glucocorticoid-dependent (but not glucocorticoid-resistant) FSGS, some authors administer the CNI with low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. Most existing data support the use of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>; however, many experts believe that cyclosporine and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> are interchangeable and preferably use tacrolimus in females because this drug is associated with fewer cosmetic side effects.</p><p>However, we avoid using CNIs in patients who have significant vascular or interstitial disease on kidney biopsy or an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m<sup>2</sup> given the additional risk of nephrotoxicity in these circumstances. Alternative therapeutic options for such patients are discussed elsewhere in this topic. (See <a class="local">'Other therapies for patients resistant or intolerant to a calcineurin inhibitor'</a> below.)</p><p>Dosing and duration of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> in patients with glucocorticoid-dependent or glucocorticoid-resistant FSGS are the same as for patients receiving these drugs as initial therapy. (See <a class="local">'Calcineurin inhibitors as alternative initial therapy'</a> above.)</p><p>Despite initial benefit, relapses are common after cessation of short-term therapy with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, although long-term kidney function is preserved. The likelihood of relapse appears to be lower if cyclosporine treatment is prolonged, perhaps up to one year or longer after remission is induced, and then gradually tapered and discontinued [<a href="#rid17">17</a>]. However, the risk of cyclosporine nephrotoxicity with prolonged therapy, particularly if the dose is ≥5 mg/kg per day, must be weighed against potential benefits [<a href="#rid17">17-19</a>]. (See  <a class="medical medical_review" href="/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p>The reported response rates with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> therapy in glucocorticoid-resistant disease range from 20 to 70 percent. Although progression of kidney disease is slowed as compared with placebo, the efficacy of cyclosporine in preventing end-stage kidney disease (ESKD) is unclear given the paucity of long-term follow-up data. The following trials illustrate the efficacy of cyclosporine among adults with glucocorticoid-resistant FSGS:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial that randomly assigned 49 adults with glucocorticoid-resistant FSGS (including 40 percent resistant to cytotoxic therapy) to low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus either <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or placebo for 26 weeks, the rate of partial or complete remission of proteinuria was higher with cyclosporine (70 versus 4 percent) [<a href="#rid20">20</a>]. Relapse was common after cyclosporine withdrawal (40 and 60 percent had worsening of proteinuria by weeks 52 and 78, respectively). At four years, patients receiving cyclosporine had a lower risk of a 50 percent reduction in creatinine clearance (25 versus 52 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second trial that randomly assigned 45 adults and children primarily with glucocorticoid-resistant FSGS to supportive therapy or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> for six months, complete or partial remission was more common with cyclosporine (59 versus 16 percent) [<a href="#rid18">18</a>]. Positive responses occurred as early as two weeks and almost all occurred within two months after initiation of therapy; lack of an antiproteinuric effect at three months was generally indicative of resistance to cyclosporine.</p><p></p><p>Compared with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, experience with <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> for the treatment of glucocorticoid-resistant FSGS is more limited. Although there are no randomized trials in this particular patient population, data from uncontrolled studies suggest that tacrolimus may be an effective alternative to cyclosporine [<a href="#rid14">14,21-25</a>].</p><p class="headingAnchor" id="H3029439985"><span class="h3">Other therapies for patients resistant or intolerant to a calcineurin inhibitor</span><span class="headingEndMark"> — </span>There is no high-quality evidence to guide the optimal therapy of patients with glucocorticoid-dependent or glucocorticoid-resistant FSGS who do not respond to, are unable to tolerate, or have contraindications to CNIs. In general, such patients should be referred to centers with appropriate expertise and considered for enrollment in a clinical trial if possible. Those with glucocorticoid-dependent FSGS may be alternatively treated with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF)/enteric-coated mycophenolate sodium (EC-MPS), <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, or cytotoxic therapy (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>). For those with glucocorticoid-resistant FSGS, commonly used alternative options to a CNI include MMF/EC-MPS and rituximab; cyclophosphamide, adrenocorticotropic hormone (ACTH), plasmapheresis, and low-density lipoprotein (LDL) apheresis are <strong>infrequently</strong> used but may be beneficial in some patients. Evidence for these therapies is presented below.</p><p class="headingAnchor" id="H2405478948"><span class="h4">Mycophenolate mofetil/sodium</span><span class="headingEndMark"> — </span>MMF/EC-MPS in combination with low-dose glucocorticoids is an alternative option for patients with glucocorticoid-dependent or glucocorticoid-resistant primary FSGS who have either not responded to or should not be exposed to CNIs, or who have had a partial response to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> and/or CNIs but developed signs of toxicity to these drugs.</p><p>If MMF is used, we give 750 to 1000 mg twice daily for six months. If EC-MPS is used, we give 540 to 720 mg twice daily for six months. MMF/EC-MPS should be administered with low-dose glucocorticoid therapy. If <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is used, we give 0.15 mg/kg per day (maximum 15 mg/day) or 0.4 mg/kg (approximately 30 mg) every other day.</p><p>Side effects associated with use of MMF/EC-MPS are discussed separately. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a>.)</p><p>Observational studies [<a href="#rid26">26-29</a>] and one randomized trial [<a href="#rid30">30</a>] suggest that MMF given with or without glucocorticoids may be beneficial in patients with FSGS [<a href="#rid26">26-29</a>]. In the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT), 138 patients with glucocorticoid-resistant primary FSGS were randomly assigned to MMF plus oral pulse <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>; all patients were given <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.3 mg/kg every other day for six months [<a href="#rid30">30</a>]. At 12 months, there was no difference between groups in rates of partial or complete remission (30 percent with MMF plus dexamethasone versus 45 percent with cyclosporine). However, the number of enrolled subjects was smaller than anticipated; whereas the trial was designed to include 500, only 138 patients were actually enrolled. Moreover, it was designed as a pediatric trial but eventually included patients up to 42 years of age. As a result, the trial was not well designed and was underpowered to detect clinically significant benefits associated with cyclosporine.</p><p class="headingAnchor" id="H2627806197"><span class="h4">Rituximab</span><span class="headingEndMark"> — </span>Several case reports have described successful use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in adults patients with glucocorticoid-dependent but <strong>not</strong> glucocorticoid-resistant FSGS; the efficacy of this therapy appears limited to patients with glucocorticoid-dependent disease [<a href="#rid31">31-34</a>]. If rituximab is used, some clinicians administer 375 mg/m<sup>2</sup> weekly for four weeks, while others prefer to administer 1 g once followed 14 days later by another 1 g dose.</p><p class="bulletIndent1"><span class="glyph">●</span>In three patients with glucocorticoid-dependent FSGS, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy (375 mg/m<sup>2</sup> weekly for four weeks) induced a complete remission, with reduction or discontinuation of other immunosuppressive drugs that persisted for at least 10 to 15 months [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, in eight patients with glucocorticoid-resistant FSGS, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> did <strong>not</strong> induce remission, although two of these patients had an improvement in proteinuria that remained above 3 g/day [<a href="#rid33">33</a>].</p><p></p><p>Side effects associated with use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> are discussed separately. (see  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>)</p><p class="headingAnchor" id="H3431132550"><span class="h4">Cytotoxic therapy</span><span class="headingEndMark"> — </span>We do <strong>not </strong>use <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in patients with primary FSGS who do not respond to an adequate trial of glucocorticoid or CNI therapy. However, cyclophosphamide may be considered in patients who have shown a partial response to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (eg, ≥50 percent reduction in protein excretion) and who have extensive interstitial fibrosis and/or vascular disease on biopsy and may therefore be at higher risk of CNI nephrotoxicity. If used, cyclophosphamide (1 to 2 mg/kg per day, maximum daily dose 200 mg) is added before prednisone has been discontinued and is administered for 8 to 12 weeks. More prolonged therapy (&gt;12 weeks) is not beneficial [<a href="#rid11">11,35</a>]. <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">Chlorambucil</a> is not recommended because of greater toxicity.</p><p>Side effects associated with use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p>Cytotoxic therapy has been used primarily in the treatment of children with relapsing or glucocorticoid-dependent idiopathic nephrotic syndrome [<a href="#rid36">36,37</a>]. In these settings, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2 mg/kg per day for 8 to 12 weeks) induced complete or partial remission in approximately 75 percent of cases [<a href="#rid36">36-39</a>].</p><p>Data on the use of cytotoxic drugs for glucocorticoid-dependent or glucocorticoid-resistant FSGS in adults are limited to a few retrospective studies and one randomized trial comparing <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, which showed no benefit with chlorambucil [<a href="#rid9">9,35</a>].</p><p class="headingAnchor" id="H1518743622"><span class="h4">Adrenocorticotropic hormone (ACTH)</span><span class="headingEndMark"> — </span>Natural ACTH gel might be effective in a variety of nephrotic diseases; it has been tested in pilot studies, most extensively in patients with idiopathic membranous nephropathy. ACTH stimulates the secretion of glucocorticoids from the adrenal cortex and is also an endogenous agonist of the melanocortin hormone system. Protective effects of melanocortin agonism have been demonstrated in an animal model of FSGS [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis", section on 'Treatment of resistant disease'</a>.)</p><p>Some patients with glucocorticoid-dependent or glucocorticoid-resistant primary FSGS may respond to natural ACTH therapy [<a href="#rid41">41,42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest observational study included 24 patients, most of whom had previously received immunosuppressive therapy that included glucocorticoids and other agents [<a href="#rid41">41</a>]; 15 patients were glucocorticoid resistant. All patients were treated with ACTH gel (80 units subcutaneously twice weekly) and followed for an average of 16 months. At some point during follow-up, two patients achieved complete remission and five patients achieved partial remission (total response rate of 29 percent), although two of these seven patients relapsed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label trial of 13 patients with treatment-resistant primary FSGS, therapy with ACTH gel (40 to 80 units two to three times weekly for six months) induced complete remission in one patient (8 percent) and partial remission in eight patients (62 percent) [<a href="#rid43">43</a>]. Among those with partial remission or no response, the addition of oral <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> (0.03 to 0.06 mg/kg/day, titrated to a trough level of 5 to 10 ng/mL) to ACTH gel for an additional six months resulted in complete remission in two patients.</p><p></p><p>These findings have not been confirmed in a randomized trial; in addition, the cost of ACTH gel in some countries may limit the capacity to test this agent. </p><p class="headingAnchor" id="H4230085074"><span class="h4">Plasmapheresis</span><span class="headingEndMark"> — </span>Based upon very limited experience, we only consider plasmapheresis in patients with primary FSGS who have continued massive proteinuria and hypoalbuminemia despite exposure to an adequate course of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, CNI, MMF/EC-MPS, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. Plasmapheresis should be performed in conjunction with immunosuppression under expert guidance. (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p>The limited role for plasmapheresis in the treatment of primary FSGS is based in part upon studies in patients who have recurrent FSGS in the kidney allograft [<a href="#rid44">44-46</a>]. In this setting, removal of a circulating factor by plasmapheresis or a protein adsorption column can dramatically reduce proteinuria and, in some cases, induce complete remission. The benefit in transplant patients may be transient, as protein excretion often returns to pretreatment levels within two months. Furthermore, the applicability of data from transplant recipients to patients with primary FSGS is unclear. (See  <a class="medical medical_review" href="/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney", section on 'Initial therapy'</a>.)</p><p>There are conflicting reports regarding benefits of plasmapheresis in treating primary FSGS:</p><p class="bulletIndent1"><span class="glyph">●</span>In one uncontrolled study of patients with refractory primary FSGS, the addition of plasmapheresis seemed beneficial in some individuals [<a href="#rid45">45</a>]. Eleven patients with biopsy-proven FSGS unresponsive to glucocorticoids and cytotoxic therapy underwent an average of 17 plasmapheresis sessions over approximately 22 weeks. At 27 months, a complete or partial response was observed in six and two patients, respectively. Among complete responders, average proteinuria fell from 5.8 to 0.9 g/day, and the plasma creatinine stabilized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, a second study reported a relatively poor response rate with plasmapheresis, with only two of eight patients experiencing transient improvement in proteinuria [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H3439937812"><span class="h4">LDL apheresis</span><span class="headingEndMark"> — </span>Several small, nonrandomized studies using variable schedules of low-density lipoprotein (LDL) apheresis in patients with glucocorticoid-resistant primary FSGS have demonstrated some benefit in terms of reduction in proteinuria and improvement in serum albumin concentration, at least in short-term follow-up [<a href="#rid47">47-51</a>]. Why this might work is unclear, but postulated mechanisms include reduction in oxidized LDL and associated inflammatory cytokines, as well as improvement in hypercoagulability. LDL apheresis is approved by the US Food and Drug Administration for adults and children with treatment-resistant primary FSGS.</p><p class="headingAnchor" id="H2680227915"><span class="h2">Patients who are pregnant</span><span class="headingEndMark"> — </span>The optimal approach to the treatment of primary FSGS in pregnant patients is not known. Most contributors of this topic would treat, preferably with glucocorticoids. <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> also appear to be safe and have been used successfully in pregnant patients. In general, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and MMF/EC-MPS should be <strong>avoided</strong> in pregnant patients. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.) </p><p>We suggest that pregnant patients with primary FSGS be referred to centers with expertise in the management of glomerular disease in pregnancy. Pregnant patients with kidney disease should be jointly managed by a nephrologist and by a maternal-fetal medicine specialist. (See  <a class="medical medical_review" href="/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease", section on 'Management during pregnancy'</a>.)</p><p>A detailed discussion of pregnancy with underlying kidney disease and the general management of nephrotic syndrome in pregnancy are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome", section on 'Management of nephrotic syndrome in pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H1620023878"><span class="h1">TREATMENT OF SECONDARY FSGS OR FSGS OF UNDETERMINED CAUSE</span><span class="headingEndMark"> — </span>Secondary FSGS most commonly refers to FSGS that develops as an adaptive response to glomerular hypertrophy or hyperfiltration but also includes secondary causes of FSGS such as drugs, toxins, and viral infections. In general, the treatment of secondary forms of FSGS focuses on cessation of the offending drug or effective treatment of the underlying condition. In addition, all patients with secondary FSGS should be treated with supportive measures (such as renin-angiotensin system inhibition, blood pressure control, and dietary sodium and protein restriction). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may also be of benefit. Glucocorticoid or calcineurin inhibitor (CNI) therapy is <strong>not </strong>recommended in such patients and may potentially cause harm. (See <a class="local">'Treatment measures for all forms of FSGS'</a> above and  <a class="medical medical_review" href="/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Pathogenesis of secondary FSGS'</a>.)</p><p>Similarly, we treat patients with FSGS of undetermined cause with supportive measures only. We do not treat such patients with glucocorticoid or CNI therapy. A repeat kidney biopsy can be considered if there is a change in the patient's clinical status (eg, development of nephrotic syndrome).</p><p class="headingAnchor" id="H2108309801"><span class="h1">TREATMENT OF GENETIC FSGS</span><span class="headingEndMark"> — </span>The optimal approach to therapy in patients with genetic mutations that have been associated with FSGS is unknown. In general, all patients with genetic FSGS should be treated with supportive measures (such as renin-angiotensin system inhibition, blood pressure control, and dietary sodium and protein restriction). SGLT2 inhibitors may also be of benefit.</p><p>Treatment with glucocorticoid or CNI therapy is generally <strong>not </strong>indicated given the low likelihood of response to these agents, although rare case reports of patients with genetic FSGS who have responded to immunosuppressive agents have been described [<a href="#rid52">52-54</a>]. Given that many patients will progress to kidney failure if left untreated, some authors would consider a trial of glucocorticoid or CNI therapy on a case-by-case basis, particularly in patients with the nephrotic syndrome and extensive foot process effacement on kidney biopsy. (See <a class="local">'Treatment measures for all forms of FSGS'</a> above and  <a class="medical medical_review" href="/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes", section on 'Clinical implications of genetic FSGS'</a>.) </p><p class="headingAnchor" id="H117802724"><span class="h1">INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>A number of investigational therapies have been proposed for the treatment of FSGS. Evidence for these therapies is discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endothelin receptor antagonists</strong> – <a class="drug drug_general" data-topicid="140820" href="/d/drug information/140820.html" rel="external">Sparsentan</a> is an oral selective antagonist of both the angiotensin II receptor and the endothelin A receptor. Endothelin 1, primarily through activation of endothelin A receptors, has been implicated in podocyte injury, proteinuria, fibrosis, and progression of chronic kidney disease [<a href="#rid55">55,56</a>]. Endothelin receptor antagonists (ERAs) have been shown to protect against kidney injury and decrease proteinuria in animal models of FSGS [<a href="#rid57">57</a>]. However, based on data from existing clinical trials, we do not use sparsentan in patients with an FSGS lesion. Sparsentan has been conditionally approved by the US Food and Drug Administration for patients with IgA nephropathy but has not been approved for patients with FSGS. </p><p></p><p class="bulletIndent1">In a phase III trial in which 371 patients with an FSGS lesion or a documented pathogenic variant in a podocyte protein associated with FSGS, urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g, and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m<sup>2</sup> were randomly assigned to <a class="drug drug_general" data-topicid="140820" href="/d/drug information/140820.html" rel="external">sparsentan</a> or <a class="drug drug_general" data-topicid="8640" href="/d/drug information/8640.html" rel="external">irbesartan</a> for up to 108 weeks, a greater proportion of sparsentan-treated patients (42 versus 26 percent) achieved a partial remission (defined as UPCR ≤1.5 g/g and &gt;40 percent reduction in UPCR from baseline) at 36 weeks, a response that was sustained through 108 weeks [<a href="#rid58">58</a>]. However, at week 108, there was no significant difference between the groups in total eGFR slope (from day 1 to week 108) or chronic eGFR slope (from week 6 to week 108). There was no significant difference in the composite of reduction in eGFR ≥40 percent, kidney failure, or death between the groups (20 percent with sparsentan and 23 percent with irbesartan). Overall rates of adverse events were comparable between the treatment groups, although hypotension, hyperkalemia, muscle spasms, elevated blood creatine kinase level, and anemia were more common among sparsentan-treated patients.</p><p></p><p class="bulletIndent1">The discrepancy between <a class="drug drug_general" data-topicid="140820" href="/d/drug information/140820.html" rel="external">sparsentan</a>'s effects on proteinuria and eGFR in this trial may reflect the enrollment of a heterogeneous mix of patients with primary, secondary, and genetic FSGS, who have a fundamentally different pathogenesis and disease course. Given that the median UPCR was 3 g/g and median serum albumin was 35 g/L, it is likely that the majority of patients had secondary or genetic FSGS. (See  <a class="medical medical_review" href="/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Differentiating between primary, secondary, and genetic FSGS'</a>.)</p><p></p><p class="bulletIndent1">A clinical trial evaluating the use of atrasentan, another ERA, in patients with FSGS is also in progress (NCT04573920).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inaxaplin</strong> – Inaxaplin (also known as VX-147) is a selective, oral small molecular inhibitor of APOL1 channel function that was designed to treat the underlying cause of proteinuric kidney disease in patients with FSGS and two <em>APOL1 </em>risk<em> </em>variant alleles (G1G1, G1G2, or G2G2). Such gain-of-function variants are thought to enhance APOL1 channel function, which results in podocyte damage. In preclinical studies, inaxaplin was shown to bind directly to the APOL1 protein, inhibit APOL1 channel function, and reduce proteinuria in a mouse model of <em>APOL1</em>-mediated kidney disease [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes", section on 'APOL1'</a>.)</p><p></p><p class="bulletIndent1">The efficacy and safety of inaxaplin were evaluated in an open-label, multicenter phase 2a clinical study in 16 adults with two <em>APOL1 </em>risk<em> </em>variants, biopsy-proven FSGS, proteinuria (UPCR ≥0.7 and &lt;10 g/g), and an eGFR ≥27 mL/min/1.73 m<sup>2</sup> [<a href="#rid59">59</a>]. At baseline, three patients had nephrotic-range proteinuria (mean UPCR 3.5 g/g), 13 had subnephrotic-range proteinuria (mean UPCR 1.8 g/g), and mean eGFR was 51 mL/min/1.73 m<sup>2</sup>. Patients received inaxaplin for 13 weeks (15 mg once daily for two weeks, followed by 45 mg once daily for 11 weeks) in addition to standard care, which could include systemic glucocorticoids, immunosuppressive agents, and renin-angiotensin inhibitors. Among the 13 patients who met the treatment-adherence threshold, the mean change from baseline UPCR at week 13 was -47.6 percent (95% CI -60 to -31.3); one patient had no reduction in proteinuria. Following completion of therapy, nine patients were followed for an additional 12 weeks; among these, mean change from baseline UPCR increased from -47.6 to -30.1 percent at week 4 and remained stable thereafter. Adverse events were mild or moderate (headache, back pain, nausea) in severity, and no patients discontinued treatment due to adverse events. While these findings are promising, additional controlled studies in a larger number of patients with uniform criteria for renin-angiotensin inhibition and immunosuppressive drug use are needed to determine longer-term efficacy and safety. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies</strong> – Other agents under investigation for patients with FSGS include <a class="drug drug_general" data-topicid="130589" href="/d/drug information/130589.html" rel="external">voclosporin</a> (calcineurin inhibitor [CNI]; NCT03598036), losmapimod (p38 mitogen-activated protein [MAP] kinase inhibitor; NCT02000440), PF-06730512 (ROBO2/SLIT2 inhibitor; NCT03448692), bleselumab (anti-CD40 monoclonal antibody; NCT02921789), <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> (NCT02592798), CCR2 inhibitors (NCT03649152, NCT03536754, NCT03703908), and Nrf2 activators (NCT03366337, NCT03422510). </p><p></p><p class="headingAnchor" id="H4101508802"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The potential efficacy of therapy must be considered in relation to the natural history of the disease. Untreated primary FSGS often follows a progressive course to end-stage kidney disease (ESKD). The rate of spontaneous complete remission among patients with nephrotic syndrome is unknown but is probably less than 10 percent. Spontaneous remission is more likely to occur among patients with normal kidney function and non-nephrotic-range proteinuria [<a href="#rid60">60</a>].</p><p>Previously, treatment was not considered to substantially improve the prognosis of FSGS. However, longer courses of treatment have resulted in response rates of up to 70 percent and improved overall prognosis. Whether the outcome of patients who present with a substantial reduction in kidney function can be altered is less clear.</p><p>Factors that appear to influence response to treatment and/or prognosis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – The most reliable prognostic indicator of kidney survival is the initial response of proteinuria to therapy (see <a class="local">'Definitions of response'</a> above). Patients who undergo partial or complete remission have a much better chance of kidney survival (approximately 80 versus &lt;50 percent at 10 years in nonresponders and untreated patients) [<a href="#rid3">3,4,8,10-12,38,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Degree of proteinuria</strong> – Patients with the nephrotic syndrome (proteinuria ≥3.5 g/day and low plasma albumin concentration) have five-year kidney survival rates of 60 to 90 percent and 10-year kidney survival rates of 30 to 55 percent [<a href="#rid8">8,38,62,63</a>]. Massive proteinuria (&gt;10 g/day), when unresponsive to treatment, is associated with an even worse prognosis, with most patients progressing to ESKD within five years [<a href="#rid8">8</a>]. By contrast, kidney survival is much better in patients without nephrotic syndrome, especially when this is associated with normal kidney function [<a href="#rid61">61</a>]. However, these observations could reflect the underlying mechanism of disease (eg, primary versus secondary FSGS).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of kidney function impairment</strong> – More severe kidney function impairment at presentation is generally associated with worse kidney survival [<a href="#rid3">3,64,65</a>]. In one series, for example, patients with a plasma creatinine concentration &gt;1.3 mg/dL (115 micromol/L) had lower 10-year kidney survival (27 versus 100 percent for those with a lower plasma creatinine) that was independent of the degree of proteinuria [<a href="#rid64">64</a>]. Worse kidney function at presentation (unless it is acute) is generally associated with a greater extent of glomerulosclerosis and interstitial fibrosis on biopsy (reflecting more severe disease, disease of longer duration, or other factors such as hypertension or aging); therefore, it is less likely to respond to therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic findings</strong> – The presence of larger amounts of interstitial fibrosis (eg, &gt;50 percent of a good biopsy sample) at the time of presentation uniformly predicts poor kidney survival, although this may reflect secondary FSGS in some cases [<a href="#rid11">11,62,65,66</a>]. Collapsing glomerulopathy is particularly associated with a worse prognosis and is often considered a unique variant associated with kidney function impairment and larger amounts of proteinuria at diagnosis [<a href="#rid67">67</a>]. The prognostic relevance of other histologic variants is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Histologic variants'</a>.)</p><p></p><p class="headingAnchor" id="H1880363693"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The goal of therapy in primary focal segmental glomerulosclerosis (FSGS) is remission of proteinuria, preferably a complete remission. This is primarily achieved with the use of a variety of agents having both immunosuppressive properties as well as direct action on glomerular podocytes (most commonly glucocorticoids or calcineurin inhibitors [CNIs]) as well as supportive measures (such as renin-angiotensin inhibition). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment measures for all forms of FSGS </strong>– General treatment measures in all patients with FSGS include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, treatment of dyslipidemia, and in selected patients, anticoagulation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may also be of benefit. (See <a class="local">'Treatment measures for all forms of FSGS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of primary FSGS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy for primary FSGS </strong>–<strong> </strong>For most patients with presumed primary FSGS who present with nephrotic syndrome (ie, proteinuria &gt;3.5 g/day and serum albumin &lt;3.5 g/dL), we suggest initial therapy with glucocorticoids, rather than a CNI (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In patients who have a high risk for glucocorticoid-induced toxicity (eg, patients with obesity, diabetes, severe osteoporosis, or age &gt;70 years), a CNI (<a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>), with or without low-dose glucocorticoids, is an alternative option for initial therapy. However, we avoid using CNIs in patients with significantly reduced kidney function (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>) because of the potential nephrotoxicity of these drugs. Dosing and duration of these regimens are discussed above. (See <a class="local">'General approach'</a> above and <a class="local">'Dosing and duration of initial therapy'</a> above.)</p><p></p><p class="bulletIndent2">By contrast, we typically do <strong>not </strong>administer glucocorticoids or CNI therapy in patients without nephrotic syndrome, with histologic evidence of extensive glomerulosclerosis and interstitial fibrosis, and with secondary, genetic, or unknown forms of FSGS. Such patients are generally treated with supportive measures only.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapsing disease</strong> – For most patients who previously had a complete or partial remission with glucocorticoids, we suggest a repeat course of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> rather than switching therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, in patients who previously developed significant adverse effects related to initial therapy with glucocorticoids, who developed a condition that increases the risk of glucocorticoid-induced toxicity, or had multiple relapses, switching to a CNI, with or without low-dose glucocorticoids, may be preferred. In such patients who have substantially reduced eGFR, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF)/enteric-coated mycophenolate sodium (EC-MPS) or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is a possible alternative. (See <a class="local">'Relapsing disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid-dependent or glucocorticoid-resistant disease</strong> – For patients with glucocorticoid-dependent or glucocorticoid-resistant FSGS, we recommend treatment with a CNI, rather than continued glucocorticoids or no therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). For patients with glucocorticoid-dependent (but not glucocorticoid-resistant) FSGS, some authors administer the CNI with low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. Patients who do not respond to, are unable to tolerate, or have contraindications to CNIs should be referred to centers with appropriate expertise and considered for enrollment in a clinical trial if possible. Those with glucocorticoid-dependent FSGS may be alternatively treated with MMF/EC-MPS, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, or cytotoxic therapy (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>). For those with glucocorticoid-resistant FSGS, commonly used alternative options to a CNI include MMF/EC-MPS and rituximab. Cyclophosphamide, adrenocorticotropic hormone (ACTH), plasmapheresis, and low-density lipoprotein (LDL) apheresis are infrequently used but may be beneficial in some patients. (See <a class="local">'Glucocorticoid-dependent or glucocorticoid-resistant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of secondary FSGS or FSGS of undetermined cause </strong>– The treatment of secondary forms of FSGS focuses on cessation of the offending drug or effective treatment of the underlying condition. All patients with secondary FSGS or FSGS of undetermined cause should receive supportive measures. Glucocorticoid or CNI therapy is <strong>not </strong>indicated in such patients. (See <a class="local">'Treatment of secondary FSGS or FSGS of undetermined cause'</a> above and <a class="local">'Treatment measures for all forms of FSGS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of genetic FSGS </strong>– The optimal approach to therapy in patients with genetic FSGS is unknown. All patients should be treated with supportive measures. Treatment with glucocorticoid or CNI therapy is generally <strong>not </strong>indicated given the low likelihood of response to these agents. (See <a class="local">'Treatment of genetic FSGS'</a> above and <a class="local">'Treatment measures for all forms of FSGS'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1.</a></li><li><a class="nounderline abstract_t">Wheeler DC, Jongs N, Stefansson BV, et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant 2022; 37:1647.</a></li><li><a class="nounderline abstract_t">Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16:1061.</a></li><li><a class="nounderline abstract_t">Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15:2169.</a></li><li><a class="nounderline abstract_t">Cattran DC, Reich HN, Beanlands HJ, et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008; 23:2247.</a></li><li><a class="nounderline abstract_t">Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002; 62:2301.</a></li><li><a class="nounderline abstract_t">Meyrier A. Nephrotic focal segmental glomerulosclerosis in 2004: an update. Nephrol Dial Transplant 2004; 19:2437.</a></li><li><a class="nounderline abstract_t">Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995; 25:534.</a></li><li><a class="nounderline abstract_t">Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32:72.</a></li><li><a class="nounderline abstract_t">Stirling CM, Mathieson P, Boulton-Jones JM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 2005; 98:443.</a></li><li><a class="nounderline abstract_t">Banfi G, Moriggi M, Sabadini E, et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991; 36:53.</a></li><li><a class="nounderline abstract_t">Pei Y, Cattran D, Delmore T, et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 1987; 82:938.</a></li><li><a class="nounderline abstract_t">Pokhariyal S, Gulati S, Prasad N, et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003; 16:691.</a></li><li><a class="nounderline abstract_t">Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004; 19:3062.</a></li><li><a class="nounderline abstract_t">Laurin LP, Gasim AM, Poulton CJ, et al. Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. Clin J Am Soc Nephrol 2016; 11:386.</a></li><li><a class="nounderline abstract_t">Jauhal A, Reich HN, Hladunewich M, et al. Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis. Nephrol Dial Transplant 2023; 38:950.</a></li><li><a class="nounderline abstract_t">Meyrier A, Noël LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie. Kidney Int 1994; 45:1446.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43:1377.</a></li><li><a class="nounderline abstract_t">Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999; 70:S26.</a></li><li><a class="nounderline abstract_t">Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56:2220.</a></li><li><a class="nounderline abstract_t">McCauley J, Shapiro R, Ellis D, et al. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 1993; 8:1286.</a></li><li><a class="nounderline abstract_t">Segarra A, Vila J, Pou L, et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002; 17:655.</a></li><li><a class="nounderline abstract_t">Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:281.</a></li><li><a class="nounderline abstract_t">Li X, Li H, Ye H, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009; 54:51.</a></li><li><a class="nounderline abstract_t">Ramachandran R, Kumar V, Rathi M, et al. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 2014; 29:1918.</a></li><li><a class="nounderline abstract_t">Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.</a></li><li><a class="nounderline abstract_t">Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17:2011.</a></li><li><a class="nounderline abstract_t">Montané B, Abitbol C, Chandar J, et al. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18:772.</a></li><li><a class="nounderline abstract_t">Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62:405.</a></li><li><a class="nounderline abstract_t">Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011; 80:868.</a></li><li><a class="nounderline abstract_t">Kronbichler A, König P, Busch M, et al. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. Wien Klin Wochenschr 2013; 125:328.</a></li><li><a class="nounderline abstract_t">Ochi A, Takei T, Nakayama K, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med 2012; 51:759.</a></li><li><a class="nounderline abstract_t">Fernandez-Fresnedo G, Segarra A, González E, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4:1317.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014; 25:850.</a></li><li><a class="nounderline abstract_t">Heering P, Braun N, Müllejans R, et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004; 43:10.</a></li><li><a class="nounderline abstract_t">Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988; 113:996.</a></li><li><a class="nounderline abstract_t">Siegel NJ, Gaudio KM, Krassner LS, et al. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981; 19:454.</a></li><li><a class="nounderline abstract_t">Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994; 23:773.</a></li><li><a class="nounderline abstract_t">Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987; 62:1102.</a></li><li><a class="nounderline abstract_t">Qiao Y, Wang P, Chang M, et al. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling. Clin Sci (Lond) 2020; 134:695.</a></li><li><a class="nounderline abstract_t">Hogan J, Bomback AS, Mehta K, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol 2013; 8:2072.</a></li><li><a class="nounderline abstract_t">Bomback AS, Canetta PA, Beck LH Jr, et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol 2012; 36:58.</a></li><li><a class="nounderline abstract_t">Tumlin J, Galphin C, Santos R, Rovin B. Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy. Kidney Int Rep 2017; 2:924.</a></li><li><a class="nounderline abstract_t">Ginsburg DS, Dau P. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 1997; 48:282.</a></li><li><a class="nounderline abstract_t">Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998; 13:1524.</a></li><li><a class="nounderline abstract_t">Feld SM, Figueroa P, Savin V, et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998; 32:230.</a></li><li><a class="nounderline abstract_t">Muso E, Mune M, Fujii Y, et al. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 2001; 89:408.</a></li><li><a class="nounderline abstract_t">Stenvinkel P, Alvestrand A, Angelin B, Eriksson M. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Invest 2000; 30:866.</a></li><li><a class="nounderline abstract_t">Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42:1121.</a></li><li><a class="nounderline abstract_t">Nakamura T, Sugaya T, Kawagoe Y, et al. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis. Clin Nephrol 2006; 65:1.</a></li><li><a class="nounderline abstract_t">Muso E, Mune M, Yorioka N, et al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 2007; 67:341.</a></li><li><a class="nounderline abstract_t">Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38:1397.</a></li><li><a class="nounderline abstract_t">Gellermann J, Stefanidis CJ, Mitsioni A, Querfeld U. Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations. Pediatr Nephrol 2010; 25:1285.</a></li><li><a class="nounderline abstract_t">Ashraf S, Kudo H, Rao J, et al. Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nat Commun 2018; 9:1960.</a></li><li><a class="nounderline abstract_t">Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014; 86:896.</a></li><li><a class="nounderline abstract_t">Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 2016; 310:R877.</a></li><li><a class="nounderline abstract_t">Ortmann J, Amann K, Brandes RP, et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44:974.</a></li><li><a class="nounderline abstract_t">Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med 2023; 389:2436.</a></li><li><a class="nounderline abstract_t">Egbuna O, Zimmerman B, Manos G, et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N Engl J Med 2023; 388:969.</a></li><li><a class="nounderline abstract_t">Deegens JK, Assmann KJ, Steenbergen EJ, et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005; 63:393.</a></li><li><a class="nounderline abstract_t">Korbet SM. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:219.</a></li><li><a class="nounderline abstract_t">Wehrmann M, Bohle A, Held H, et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990; 33:115.</a></li><li><a class="nounderline abstract_t">Velosa JA, Torres VE. Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome. Am J Kidney Dis 1986; 8:345.</a></li><li><a class="nounderline abstract_t">Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998; 9:1333.</a></li><li><a class="nounderline abstract_t">Chitalia VC, Wells JE, Robson RA, et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999; 56:2236.</a></li><li><a class="nounderline abstract_t">Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69:920.</a></li><li><a class="nounderline abstract_t">Laurin LP, Gasim AM, Derebail VK, et al. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol 2016; 11:1752.</a></li></ol></div><div id="topicVersionRevision">Topic 3100 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556256" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850160" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716334" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284302" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182409" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The impact of sex in primary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427162" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of primary focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280528" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nephrotic focal segmental glomerulosclerosis in 2004: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702047" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669427" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term outcome in children and adults with classic focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15879445" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1934660" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578362" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14733415" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507477" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26912551" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948275" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8072258" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Sociétéde Néphrologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315953" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369192" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of focal segmental glomerulosclerosis: evidence-based recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594798" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7508098" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11917061" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14758528" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406543" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849465" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mycophenolate mofetil treatment for primary glomerular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401863" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811652" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630898" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21734640" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical trial of focal segmental glomerulosclerosis in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23624956" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466834" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rituximab treatment for adult patients with focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578004" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480824" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14712422" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3193322" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7241883" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203357" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Primary focal segmental glomerulosclerosis: clinical course and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688915" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32167144" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24009220" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722778" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29270498" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403211" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9641186" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708606" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11721158" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11029600" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655182" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16429835" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598368" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17086182" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20191369" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773874" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24805108" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endothelin and endothelin antagonists in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27009050" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545511" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37921461" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36920755" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301760" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704582" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2323110" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3788972" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9644647" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Primary focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594800" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Predicting renal survival in primary focal glomerulosclerosis from the time of presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518352" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27445167" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
